Cardiac Pacemaker Revision Except Device Replacement with CC DRG Reimbursement

DRG 261 encompasses inpatient cardiac pacemaker system revision procedures except full device replacement when a Complication or Comorbidity exists; it covers interventions such as lead or pocket revisions and management of device-related complications. This Diagnosis-Related Group matters for inpatient reimbursement because it groups similar resource use and clinical complexity to determine Medicare payment levels.

DRG 261 Overview

DRG 261 covers inpatient admissions for cardiac pacemaker system revision procedures, excluding full device replacement, when a Complication or Comorbidity is present. Typical cases include lead revision, pocket revision, generator connector interventions, or treatment of device-related complications short of total system replacement. This Diagnosis-Related Group is clinically focused on device system management and related complications and influences Medicare payment by grouping resource use for these revision procedures with an added severity element due to the Complication or Comorbidity.

Acute procedural optimization studies: Trials that evaluate perioperative techniques and device programming strategies during inpatient pacemaker revision procedures, focusing on minimizing intraoperative complications (lead extraction, pocket issues) and immediate post-procedure adverse events. These studies typically enroll patients admitted for revision due to lead malfunction, infection, erosion, or sensing/pacing failure and compare different surgical approaches, lead management protocols, or anesthetic pathways. Results are relevant to surgeons and hospital administrators because optimized intraoperative care can reduce length of stay, complication-related costs, and readmissions—key drivers of reimbursement under this DRG.
Comparative effectiveness and device-strategy trials: Research comparing clinical outcomes and resource use between specific revision strategies such as lead-sparing revision versus lead extraction and reimplantation, or conservative device reprogramming versus hardware intervention in patients with comorbid cardiac disease. These studies target a heterogeneous inpatient population including older adults with heart failure, chronic kidney disease, or prior device infections, and aim to clarify which approaches yield better survival, fewer complications, and lower downstream utilization. Findings inform payer and clinician decisions about which interventions provide the best value and can guide preauthorization and care pathway development for DRG fiscal planning.
Post-discharge outcomes and readmission prevention studies: Cohort and interventional studies that follow patients after pacemaker revision hospitalization to evaluate predictors of 30-day readmission, infection recurrence, functional recovery, and health-related quality of life, often testing care bundles, remote monitoring, or structured follow-up clinics. These studies focus on medically complex inpatients prone to early readmission (frail elders, those with diabetes or immune compromise) and assess interventions to reduce post-discharge complications and emergency returns. Evidence from this research is critical to hospitals and payers because reducing readmissions and complications improves patient outcomes and decreases costs associated with penalties and DRG-based reimbursements.

Acute procedural optimization studies: Trials that evaluate perioperative techniques and device programming strategies during inpatient pacemaker revision procedures, focusing on minimizing intraoperative complications (lead extraction, pocket issues) and immediate post-procedure adverse events. These studies typically enroll patients admitted for revision due to lead malfunction, infection, erosion, or sensing/pacing failure and compare different surgical approaches, lead management protocols, or anesthetic pathways. Results are relevant to surgeons and hospital administrators because optimized intraoperative care can reduce length of stay, complication-related costs, and readmissions—key drivers of reimbursement under this DRG.
Comparative effectiveness and device-strategy trials: Research comparing clinical outcomes and resource use between specific revision strategies such as lead-sparing revision versus lead extraction and reimplantation, or conservative device reprogramming versus hardware intervention in patients with comorbid cardiac disease. These studies target a heterogeneous inpatient population including older adults with heart failure, chronic kidney disease, or prior device infections, and aim to clarify which approaches yield better survival, fewer complications, and lower downstream utilization. Findings inform payer and clinician decisions about which interventions provide the best value and can guide preauthorization and care pathway development for DRG fiscal planning.
Post-discharge outcomes and readmission prevention studies: Cohort and interventional studies that follow patients after pacemaker revision hospitalization to evaluate predictors of 30-day readmission, infection recurrence, functional recovery, and health-related quality of life, often testing care bundles, remote monitoring, or structured follow-up clinics. These studies focus on medically complex inpatients prone to early readmission (frail elders, those with diabetes or immune compromise) and assess interventions to reduce post-discharge complications and emergency returns. Evidence from this research is critical to hospitals and payers because reducing readmissions and complications improves patient outcomes and decreases costs associated with penalties and DRG-based reimbursements.

OpenPayer

Summary & Overview

Cardiac Pacemaker Revision Except Device Replacement with CC: Inpatient Reimbursement Overview

DRG 261 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes